Technologies Available for Partnering

Our commitment to innovative research spans a wide spectrum of technologies. From uncovering novel therapeutic targets and pioneering precise diagnostics platforms to harnessing the power of artificial intelligence to expedite the pace of discovery, we push the boundaries of what’s possible in the fight against cancer and related disease.

Showing 37-48 of 54

Small Molecule Inhibition Targeting Kinases ERK5, PIkI, MPSI as a Therapeutic Strategy in Cardiovascular Disease, Prostate Cancer, and Glioblastoma

Licensing

Antisense Oligonucleotides for the Treatment of RAS Q61 Mutant Cancers

Collaboration
Licensing

Dual Inhibition of MDM2 and MDM4 Enhances Treatment Response of p53 WT Tumors

Collaboration
Investment
Licensing

Methods for Modulating MHC-I Expression in Merkel Cell Carcinoma

Licensing

Antisense Inhibitors of Long Noncoding RNA as Treatment for Multiple Myeloma

Licensing

Highly Selective Focal Adhesion Kinase (FAK) Inhibitors

Licensing

Methods of Treating Cancers Using STING Agonists

Collaboration
Licensing

Enhanced Cell Immunotherapy Approach Using Multi-Specific Cytotoxic CD4+ T Cells

Licensing

Allosteric EGFR Inhibition May Improve Outcomes for Non-Small Cell Lung Cancer

Licensing

Targeting BFL-1 Reactivates Cancer Cell Death

Collaboration
Licensing

First-in-Class, Dual Degraders of IRAK 1 and IRAK 4 for MyD88-Mutant Blood Cancers

Collaboration
Licensing

Small Molecule Inhibitors for the Treatment of VEXAS Syndrome

Collaboration

microscopic image of